Abstract
OBJECTIVES: This study was carried out to investigate the ameliorative effect of Atorvastatin on Cisplatin-induced Nephrotoxicity in Wistar rats. METHODS: Twenty Four (24) male rats were used for the experiment. Group I was administered per oral daily with Phosphate Buffered Saline (PBS) for 10 days. Group II was administered single intraperitoneal dose of Cisplatin 7.5mg kg-1 body weight on fifth day, Group III was administered daily per oral dose of Atorvastatin 3 mg kg- 1 body weight for 10 days and on fifth day single intraperitoneal dose of Cisplatin 7.5 mg kg-1 body weight. Group IV was administereddaily per oral dose of Atorvastatin 10 mg kg-1 body weight for 10 days and on fifth day a single intraperitoneal dose of Cisplatin 7.5 mg kg-1 body weight. After the last day of treatment animals were sacrificed and blood samples collected by cardiac puncture and used for analysis of serum creatinine, blood urea nitrogen and total protein. The antioxidant parameters of Catalase, GSH and TBARS were measured in kidneys. RESULTS: The result showed a significantly reduced serum concentration of creatinine, urea and total protein in groups treated with Cisplatin only when compared to PBS. CONCLUSION: It is concluded that the decrease in creatinine, blood urea and total protein were ameliorated by the administration of atorvastatin which may be due to its antioxidant properties.
References
REFERENCES:
Burger H, Loose WJ, Eechoute K., Verweij J, Mathijssen RH, Wiemer EA. (2011) Drug Resistance Updates, 14:22-34. DOI: 10.1016/j.drup.2010.12.002.
Sahu BD, Rentam KK, Putcha UK., Kuncha M, Vegi GM, Sistla R. (2011) Food Chemical. Toxicol, 49:3090- 3097. DOI: 10.1016/j.fct.2011.08.018.
Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. (2007) Archives Toxicol, 81: 495-504. DOI: 10.1007/s00204-006-0173-2.
Pabla N, Z Dong. (2008) Kidney Int, 2008;73:994–1007.
Marcin R, Tylicki L, Rutkowski P, Neuwelt A, Larczynski W, Zietkiewicz M, Alesksadrowicz E, Lysiak- Szydloewskaw,W, Rutkowski B. (2010) J. Polish Biochemical Society Committee Biochemistry Biophysics Polish Acad. Sci, 57:547-552.
Jeong YK., Eun YL, Eun BL, Yun JL., Hyun JY, Jiyong C, Yeong WS. (2012) Arthritis Research & Therapy, 14:187. DOI:10.1186/ar4018.
Gao C, Wei L, Zhi-dan S, Shi-guang Z, Xiangzhen L. (2009). BMC Neuroscience, 10:7-10. DOI: 10.1186/1471-2202-10-7.
Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. (2002) Arterioscler Thromb Vasc Biol, 22: 300-305. DOI: 10.1161/hq0202.104081.
Ohkawa M, Ohishi N, Yagi K. (1979). Anal. Biochem, 95: 351-8. DOI: 10.1016/0003-2697 (79) 90738-3.
Aebi HC, Bergmeyer HU: “Methods of enzymatic analysis”, Academic Press, New York, London, 1st 1974.
Ellman GL. (1959) Arch Biochem. Biophys, 82: 70-77. DOI: 10.1016/0003-9861(59)90090-6
Hesketh MA, Twaddell T, Finn A. (1990) Proc Am Assoc ClinOncol, 9:323-326.
Cavalli F, Tschopp L, Sonnatag RW, Zimmermann A. (1978) Cancer Treat Rep, 62: 2125-2126.
Koc A, Duru M, Ciralik H, Akcan R, Sougut S. (2005) Mol. Cell Biochem, 278:79-84. DOI: 10.1007/s11010- 005-6630-z.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. (2010) Toxins. 2:2490–2518.
Fujieda M, Morita T, Naruse K, Hayashi Y, Ishihara M, Yokoyama T, Toma T, Ohta K, Wakiquchi H. (2011) Hum ExpToxicol, 30:603-15. DOI: 10.1177/0960327110376551.
Santoso A, Lucci JA, Coleman RL, Schafer I, Hannigan EV. (2003) CancerChemotherPharmacol, 52: 13-8. DOI: 10.1007/s00280-003-0620-1.
Taguchi T, Nazneen A, Abid MR, Razzaque MS. (2005) Contrib Nephrol, 148:107-21. DOI: 10.1159/000086055.
Simon CMK, Solomon P, Samuel B, John HB. (2012) J. Cell Mol. Med, 16:394-400. DOI: 10.1111/j.1582- 4934.2011.01324.x.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array